Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S BARTLETT

Showing results (351-360 of 386) with videos related to

Pageof 39
Sort By:
Cancer Research|October 29, 2021
Heterogeneity of Circulating Tumor Cell-Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune ResponseNisha Kanwar, Zaldy Balde, Ranju Nair, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2020
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic CancerGrainne M O'Kane, Barbara T Grünwald, Gun-Ho Jang, et al.
Nature Communications|November 14, 2018
Pathway-based subnetworks enable cross-disease biomarker discoverySyed Haider, Cindy Q Yao, Vicky S Sabine, et al.
Breast Cancer Research and Treatment|June 23, 2025
Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozoleJudith-Anne W Chapman, Jane Bayani, Sandip SenGupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2024
Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus AnastrozoleJudith-Anne W Chapman, Jane Bayani, Sandip SenGupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2022
Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic CancerGrainne M O'Kane, Barbara T Grünwald, Gun-Ho Jang, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 26, 2018
An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancerDavid L Rimm, Samuel C Y Leung, Lisa M McShane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2020
A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic CancerJoan M Romero, Barbara Grünwald, Gun-Ho Jang, et al.
Cancers|October 13, 2021
Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working GroupMieke R Van Bockstal, Maxine Cooks, Iris Nederlof, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Pageof 39

Showing results (351-360 of 386) with videos related to

Sort By:
Pageof 39
Cancer Research|October 29, 2021
Heterogeneity of Circulating Tumor Cell-Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune ResponseNisha Kanwar, Zaldy Balde, Ranju Nair, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2020
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic CancerGrainne M O'Kane, Barbara T Grünwald, Gun-Ho Jang, et al.
Nature Communications|November 14, 2018
Pathway-based subnetworks enable cross-disease biomarker discoverySyed Haider, Cindy Q Yao, Vicky S Sabine, et al.
Breast Cancer Research and Treatment|June 23, 2025
Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozoleJudith-Anne W Chapman, Jane Bayani, Sandip SenGupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2024
Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus AnastrozoleJudith-Anne W Chapman, Jane Bayani, Sandip SenGupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2022
Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic CancerGrainne M O'Kane, Barbara T Grünwald, Gun-Ho Jang, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 26, 2018
An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancerDavid L Rimm, Samuel C Y Leung, Lisa M McShane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2020
A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic CancerJoan M Romero, Barbara Grünwald, Gun-Ho Jang, et al.
Cancers|October 13, 2021
Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working GroupMieke R Van Bockstal, Maxine Cooks, Iris Nederlof, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Pageof 39